B and T lymphocyte attenuator

Home
Ligands
B and T lymphocyte attenuator (Human)

GtoPdb Ligand ID: 4891

Abbreviated name: BTLA

Synonyms: B- and T-lymphocyte attenuator | B- and T-lymphocyte-associated protein | CD272

Compound class: Endogenous peptide in human, mouse or rat

Comment: BTLA is a negative immunomodulator. Interaction of BTLA with TNFRSF14 (HVEM) constitutes an immune checkpoint which inhibits T cell-mediated immune responses. Dysregulated BTLA expression contributes to immunosuppression and progression of some cancers [1-4] by enabling tumour immune evasion. Immunotherapeutics that target the BTLA-HVEM checkpoint offer potential as anti-tumour agents [5-6].

Species: Human

Summary
Biological activity
References
Structure
Immunopharmacology

Immunopharmacology Comments
BTLA is principally expressed on T and B lymphocytes, dendritic cells and macrophages. It mediates immunosuppression by inhibiting T and B cell proliferation and activity.

Immunopharmacology Comments

BTLA is principally expressed on T and B lymphocytes, dendritic cells and macrophages. It mediates immunosuppression by inhibiting T and B cell proliferation and activity.